Genelux Corp (GNLX)

$2.97 +0.07 (2.41%)
Market Cap 130.04M
Revenue (ttm) 10,000.00
Net Income (ttm) -32.15M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -321,500.02%
Debt to Equity Ratio 0.00
Volume 137,100
Avg Vol 190,924
Day's Range N/A - N/A
Shares Out 44.84M
Stochastic %K 65%
Beta 0.51
Analysts Strong Sell
Price Target $19.00

Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and e...

Industry: Biotechnology
Sector: Healthcare
Phone: 805 267 9889
Address:
2625 Townsgate Road, Suite 230, Westlake Village, United States
justiceforb_85
justiceforb_85 May. 10 at 9:22 PM
$GNLX wondering why this has done so poorly? Is there concern for dilution? Drug appears active in ovarian ca but wondering why they are going after lung cancer (where there is significant competition)?
0 · Reply
FrodoBag
FrodoBag May. 8 at 10:09 PM
$GNLX this tanked when they pushed back top line results to 2H. Now finally above 3 again on news that those results are still on track for 2H…
0 · Reply
bkfViking123
bkfViking123 Apr. 28 at 3:30 PM
back in starter shares of $GNLX while it's under the radar ... 2026 is the year if it hits
1 · Reply
Kupper
Kupper Apr. 21 at 3:21 PM
$GNLX Up one week down the next week. When will this get the attention it deserves.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 14 at 3:52 PM
$GNLX RSI: 57.69, MACD: -0.0247 Vol: 0.10, MA20: 2.55, MA50: 2.62 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Kupper
Kupper Apr. 9 at 3:39 PM
$GNLX what is causing the negative price action on this?
3 · Reply
Kupper
Kupper Mar. 30 at 7:29 PM
$GNLX this is getting rediculously cheap.
1 · Reply
KC1391
KC1391 Mar. 30 at 1:46 PM
$GNLX is this a buy again now? Buy low sell high
0 · Reply
Shawnkick007
Shawnkick007 Mar. 25 at 2:05 PM
$GNLX I swear when this thing gets back up to $40 I’m selling this turd.
1 · Reply
anachartanalyst
anachartanalyst Mar. 20 at 5:02 PM
$GNLX https://anachart.com/wp-content/uploads/ana_temp/1774026109_soc-img.jpg
0 · Reply
Latest News on GNLX
Genelux reports Q1 EPS (20c), consensus (19c)

2026-05-07T23:07:18.000Z - 5 days ago

Genelux reports Q1 EPS (20c), consensus (19c)

Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates

May 7, 2026, 4:15 PM EDT - 5 days ago

Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates

Genelux price target lowered to $20 from $23 at Benchmark

2026-03-20T12:36:29.000Z - 7 weeks ago

Genelux price target lowered to $20 from $23 at Benchmark

Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Mar 19, 2026, 4:15 PM EDT - 7 weeks ago

Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners

Jan 12, 2026, 4:00 PM EST - 4 months ago

Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners

Genelux prices 6.67M shares at $3.00 in underwritten public offering

2026-01-08T14:21:22.000Z - 4 months ago

Genelux prices 6.67M shares at $3.00 in underwritten public offering

Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock

Jan 8, 2026, 9:13 AM EST - 4 months ago

Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock

Genelux announces common stock offering, no amount given

2026-01-07T21:05:55.000Z - 4 months ago

Genelux announces common stock offering, no amount given

Genelux Corporation Announces Proposed Public Offering of Common Stock

Jan 7, 2026, 4:01 PM EST - 4 months ago

Genelux Corporation Announces Proposed Public Offering of Common Stock

Genelux data update indicates disease early control, says H.C. Wainwright

2026-01-05T15:55:27.000Z - 4 months ago

Genelux data update indicates disease early control, says H.C. Wainwright

Genelux reports interim data of systemic administration of Olvi-Vec

2026-01-05T13:25:52.000Z - 4 months ago

Genelux reports interim data of systemic administration of Olvi-Vec

Genelux appoints Jason Litten as CMO

2026-01-02T13:05:23.000Z - 4 months ago

Genelux appoints Jason Litten as CMO

Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer

Jan 2, 2026, 8:00 AM EST - 4 months ago

Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer

Genelux reports Q3 EPS (21c), consensus (21c)

2025-11-05T23:00:37.000Z - 6 months ago

Genelux reports Q3 EPS (21c), consensus (21c)

Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates

Nov 5, 2025, 4:20 PM EST - 6 months ago

Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates

Genelux initiated with a Buy at Titan Partners

2025-10-31T15:55:12.000Z - 6 months ago

Genelux initiated with a Buy at Titan Partners

Genelux price target raised to $20 from $10 at Maxim

2025-10-21T17:10:40.000Z - 7 months ago

Genelux price target raised to $20 from $10 at Maxim

REPL

Genelux initiated with a Buy at Lake Street

2025-10-21T12:00:50.000Z - 7 months ago

Genelux initiated with a Buy at Lake Street

Genelux reports Q2 EPS (20c), consensus (22c)

2025-08-07T22:00:35.000Z - 9 months ago

Genelux reports Q2 EPS (20c), consensus (22c)

Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates

Aug 7, 2025, 4:20 PM EDT - 9 months ago

Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates

Genelux initiated with a Buy at Lucid Capital

2025-07-21T11:17:30.000Z - 10 months ago

Genelux initiated with a Buy at Lucid Capital

Genelux appoints Eric Groen as general counsel, corporate secretary, CCO

2025-07-07T11:11:07.000Z - 11 months ago

Genelux appoints Eric Groen as general counsel, corporate secretary, CCO

RANI

Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development

Jul 7, 2025, 7:00 AM EDT - 11 months ago

Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development

Genelux reports Q1 EPS (21c), consensus (24c)

2025-05-06T21:15:11.000Z - 1 year ago

Genelux reports Q1 EPS (21c), consensus (24c)

Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates

May 6, 2025, 4:10 PM EDT - 1 year ago

Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates

Genelux reports FY24 EPS (95c), consensus (88c)

2025-03-28T20:15:24.000Z - 1 year ago

Genelux reports FY24 EPS (95c), consensus (88c)

Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 28, 2025, 4:10 PM EDT - 1 year ago

Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Genelux, Newsoara announce preliminary Phase 1b/2 data of Olvi-Vec

2025-03-25T18:29:53.000Z - 1 year ago

Genelux, Newsoara announce preliminary Phase 1b/2 data of Olvi-Vec

Genelux announces alignment with FDA of approval pathway for Olvi-Vec

2025-03-25T18:29:16.000Z - 1 year ago

Genelux announces alignment with FDA of approval pathway for Olvi-Vec

Genelux prices 3M shares at $3.50 in underwritten public offering

2025-03-25T18:26:09.000Z - 1 year ago

Genelux prices 3M shares at $3.50 in underwritten public offering

Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock

Mar 25, 2025, 8:31 AM EDT - 1 year ago

Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock

One new option listing on February 19th

2025-02-19T13:36:46.000Z - 1 year ago

One new option listing on February 19th

Genelux Corporation Announces New Chief Financial Officer

Feb 3, 2025, 6:45 AM EST - 1 year ago

Genelux Corporation Announces New Chief Financial Officer

Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright

Dec 13, 2024, 7:01 AM EST - 1 year ago

Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright

Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference

Nov 6, 2024, 4:01 PM EST - 1 year ago

Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference

Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer

Oct 22, 2024, 4:01 PM EDT - 1 year ago

Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer

Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 9, 2024, 4:15 PM EDT - 1 year ago

Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit

Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference

Sep 3, 2024, 4:01 PM EDT - 1 year ago

Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference

Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates

Aug 14, 2024, 4:05 PM EDT - 1 year ago

Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates

Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2024

Jul 30, 2024, 7:00 AM EDT - 1 year ago

Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2024

Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants

May 24, 2024, 8:00 AM EDT - 2 years ago

Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants

Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants

May 23, 2024, 4:01 PM EDT - 2 years ago

Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants

Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates

May 9, 2024, 4:25 PM EDT - 2 years ago

Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates

Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Apr 1, 2024, 7:00 AM EDT - 2 years ago

Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer

Nov 27, 2023, 7:00 AM EST - 2 years ago

Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer

Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates

Nov 14, 2023, 5:50 PM EST - 2 years ago

Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates

Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 14, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates

Aug 14, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates

Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2023

Aug 2, 2023, 4:00 PM EDT - 3 years ago

Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2023

Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires

Jul 20, 2023, 4:45 PM EDT - 3 years ago

Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires

Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology

Jul 10, 2023, 7:00 AM EDT - 3 years ago

Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology

Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLC

Jun 29, 2023, 7:00 AM EDT - 3 years ago

Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLC

Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023

Jun 22, 2023, 7:00 AM EDT - 3 years ago

Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023

Genelux Corporation Announces $18 Million Private Placement

Jun 12, 2023, 7:00 AM EDT - 3 years ago

Genelux Corporation Announces $18 Million Private Placement

Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) On

May 25, 2023, 4:01 PM EDT - 3 years ago

Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) On

Genelux Corporation Announces $33 Million Private Placement

May 15, 2023, 7:00 AM EDT - 3 years ago

Genelux Corporation Announces $33 Million Private Placement

Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023

Mar 23, 2023, 7:00 AM EDT - 3 years ago

Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023

Genelux IPO prices at bottom of range

Jan 26, 2023, 6:40 AM EST - 3 years ago

Genelux IPO prices at bottom of range

Genelux Corporation Announces Pricing of Initial Public Offering

Jan 25, 2023, 9:00 PM EST - 3 years ago

Genelux Corporation Announces Pricing of Initial Public Offering

Genelux sets IPO terms, as the biotech could be valued at up to $165 millino

Sep 19, 2022, 9:08 AM EDT - 3 years ago

Genelux sets IPO terms, as the biotech could be valued at up to $165 millino

justiceforb_85
justiceforb_85 May. 10 at 9:22 PM
$GNLX wondering why this has done so poorly? Is there concern for dilution? Drug appears active in ovarian ca but wondering why they are going after lung cancer (where there is significant competition)?
0 · Reply
FrodoBag
FrodoBag May. 8 at 10:09 PM
$GNLX this tanked when they pushed back top line results to 2H. Now finally above 3 again on news that those results are still on track for 2H…
0 · Reply
bkfViking123
bkfViking123 Apr. 28 at 3:30 PM
back in starter shares of $GNLX while it's under the radar ... 2026 is the year if it hits
1 · Reply
Kupper
Kupper Apr. 21 at 3:21 PM
$GNLX Up one week down the next week. When will this get the attention it deserves.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 14 at 3:52 PM
$GNLX RSI: 57.69, MACD: -0.0247 Vol: 0.10, MA20: 2.55, MA50: 2.62 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Kupper
Kupper Apr. 9 at 3:39 PM
$GNLX what is causing the negative price action on this?
3 · Reply
Kupper
Kupper Mar. 30 at 7:29 PM
$GNLX this is getting rediculously cheap.
1 · Reply
KC1391
KC1391 Mar. 30 at 1:46 PM
$GNLX is this a buy again now? Buy low sell high
0 · Reply
Shawnkick007
Shawnkick007 Mar. 25 at 2:05 PM
$GNLX I swear when this thing gets back up to $40 I’m selling this turd.
1 · Reply
anachartanalyst
anachartanalyst Mar. 20 at 5:02 PM
$GNLX https://anachart.com/wp-content/uploads/ana_temp/1774026109_soc-img.jpg
0 · Reply
Kupper
Kupper Mar. 3 at 6:45 PM
$GNLX why the drop in share price today?
1 · Reply
BillionerOfKing
BillionerOfKing Mar. 2 at 7:14 PM
$GNLX Current Stock Price: $2.91 Contracts to trade: $5.0 GNLX Mar 20 2026 Call Entry: $0.05 Exit: $0.06 ROI: 31% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
PortfolioOverture
PortfolioOverture Feb. 20 at 2:13 PM
$GNLX Genelux develops oncolytic virus therapies. Clinical milestones are the primary catalyst. Early-stage risk remains high.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 12 at 10:32 PM
$GNLX RSI: 32.73, MACD: -0.3002 Vol: 0.19, MA20: 2.66, MA50: 3.47 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BounceRaider
BounceRaider Feb. 10 at 1:05 PM
$GNLX is a biotech (Genelux) focused on oncolytic viruses; clinical development is high-risk and capital intensive.
0 · Reply
05ford
05ford Feb. 5 at 4:41 AM
$GNLX boy this thing needs a good shot in the arm.
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Jan. 16 at 8:04 PM
$GNLX $3.00 Possible on this break of resistance we have another overnight swing winner... Keep it going🚨🚨
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 15 at 11:26 AM
$GNLX Current Stock Price: $2.61 Contracts to trade: $2.5 GNLX Jan 16 2026 Call Entry: $2.34 Exit: $4.10 ROI: 75% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
garygb
garygb Jan. 11 at 2:44 PM
$GNLX Holding and adding.My guess is it's bottomed out.
0 · Reply
PaulThomasTPG
PaulThomasTPG Jan. 9 at 2:22 AM
$FNMA $BBAI Its feels like forever ago, that these were trading as penny stocks! $GNLX running all the way to 250% in 11months, and then plummeting 80% in a month is pretty WILD! https://www.youtube.com/watch?v=8ed505uoqpk
0 · Reply